Brought to you by 
AstraZeneca, Pozen co-develop chronic pain treatment; US rights sublicensed to Horizon
21 Jan 2016
Executive Summary
Pain therapeutics company Pozen and AstraZeneca have teamed up to develop a fixed-dose tablet combining the non-steroidal anti-inflammatory (NSAID) drug naproxen with the proton pump inhibitor esomeprazole to treat chronic pain and inflammation in patients at risk for developing NSAID-related gastric ulcers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca, Pozen co-develop chronic pain treatment; US rights sublicensed to Horizon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice